Flow cytometric evaluation of lymphoid and myeloid populations in mice repopulated with cux/CDPΔHD/ΔHDbone marrow
| Populations* . | CT . | ΔHD . | ||
|---|---|---|---|---|
| % cells† . | No. cells × 107‡ . | % cells† . | No. cells × 107‡ . | |
| Bone marrow | N/A | (3.29 ± 0.42) | N/A | (3.11 ± 0.39) |
| B220+ | 37.3 ± 3.2 | (1.16 ± 0.21) | 22.4 ± 1.72-153 | (0.67 ± 0.09)2-153 |
| B220+c-Kit+ | 4.9 ± 1.2 | (0.16 ± 0.06) | 3.2 ± 0.82-155 | (0.09 ± 0.02)2-153 |
| B220+CD25+ | 4.8 ± 2.9 | (0.20 ± 0.15) | 2.0 ± 1.0 | (0.07 ± 0.04) |
| B220+IgM+ | 16.3 ± 3.0 | (0.52 ± 0.16) | 8.1 ± 0.52-153 | (0.24 ± 0.04)2-153 |
| Mac-1+B220− | 52.8 ± 2.3 | (1.64 ± 0.25) | 68.3 ± 5.02-153 | (2.05 ± 0.37) |
| Spleen | N/A | (10.5 ± 3.8) | N/A | (13.3 ± 4.7) |
| B220+ | 70.0 ± 2.9 | (7.4 ± 3.0) | 69.4 ± 4.6 | (9.2 ± 3.4) |
| Mac-1+B220− | 4.7 ± 1.1 | (0.48 ± 0.22) | 5.9 ± 2.1 | (0.74 ± 0.36) |
| CD4+ | 16.1 ± 3.9 | (1.4 ± 0.4) | 16.7 ± 4.1 | (1.84 ± 0.8) |
| CD8+ | 6.5 ± 1.1 | (0.55 ± 0.21) | 5.7 ± 1.9 | (0.77 ± 0.33) |
| Thymus | N/A | (11.3 ± 2.3) | N/A | (9.2 ± 2.9) |
| lin−CD4−CD8− | 0.8 ± 0.1 | (0.1 ± 0.0) | 0.7 ± 0.3 | (0.1 ± 0.0) |
| CD4+CD8+ | 83 ± 0.9 | (9.3 ± 1.9) | 86 ± 1.82-155 | (7.9 ± 2.5) |
| CD4+CD8− | 12 ± 1.1 | (1.3 ± 0.3) | 9.9 ± 1.52-155 | (0.9 ± 0.2)2-155 |
| CD4−CD8+ | 3.8 ± 0.6 | (0.4 ± 0.1) | 3.3 ± 0.7 | (0.3 ± 0.1) |
| CD3intCD25int | 1.0 ± 0.2 | (0.1 ± 0.0) | 3.9 ± 0.32-153 | (0.4 ± 0.1)2-153 |
| Populations* . | CT . | ΔHD . | ||
|---|---|---|---|---|
| % cells† . | No. cells × 107‡ . | % cells† . | No. cells × 107‡ . | |
| Bone marrow | N/A | (3.29 ± 0.42) | N/A | (3.11 ± 0.39) |
| B220+ | 37.3 ± 3.2 | (1.16 ± 0.21) | 22.4 ± 1.72-153 | (0.67 ± 0.09)2-153 |
| B220+c-Kit+ | 4.9 ± 1.2 | (0.16 ± 0.06) | 3.2 ± 0.82-155 | (0.09 ± 0.02)2-153 |
| B220+CD25+ | 4.8 ± 2.9 | (0.20 ± 0.15) | 2.0 ± 1.0 | (0.07 ± 0.04) |
| B220+IgM+ | 16.3 ± 3.0 | (0.52 ± 0.16) | 8.1 ± 0.52-153 | (0.24 ± 0.04)2-153 |
| Mac-1+B220− | 52.8 ± 2.3 | (1.64 ± 0.25) | 68.3 ± 5.02-153 | (2.05 ± 0.37) |
| Spleen | N/A | (10.5 ± 3.8) | N/A | (13.3 ± 4.7) |
| B220+ | 70.0 ± 2.9 | (7.4 ± 3.0) | 69.4 ± 4.6 | (9.2 ± 3.4) |
| Mac-1+B220− | 4.7 ± 1.1 | (0.48 ± 0.22) | 5.9 ± 2.1 | (0.74 ± 0.36) |
| CD4+ | 16.1 ± 3.9 | (1.4 ± 0.4) | 16.7 ± 4.1 | (1.84 ± 0.8) |
| CD8+ | 6.5 ± 1.1 | (0.55 ± 0.21) | 5.7 ± 1.9 | (0.77 ± 0.33) |
| Thymus | N/A | (11.3 ± 2.3) | N/A | (9.2 ± 2.9) |
| lin−CD4−CD8− | 0.8 ± 0.1 | (0.1 ± 0.0) | 0.7 ± 0.3 | (0.1 ± 0.0) |
| CD4+CD8+ | 83 ± 0.9 | (9.3 ± 1.9) | 86 ± 1.82-155 | (7.9 ± 2.5) |
| CD4+CD8− | 12 ± 1.1 | (1.3 ± 0.3) | 9.9 ± 1.52-155 | (0.9 ± 0.2)2-155 |
| CD4−CD8+ | 3.8 ± 0.6 | (0.4 ± 0.1) | 3.3 ± 0.7 | (0.3 ± 0.1) |
| CD3intCD25int | 1.0 ± 0.2 | (0.1 ± 0.0) | 3.9 ± 0.32-153 | (0.4 ± 0.1)2-153 |
N/A indicates not applicable.
Hematopoietic tissues from six 8-week-posttransplantation recipients (10-11 months for B220+CD25+populations) reconstituted with cux/CDPΔHD/ΔHD (ΔHD) and control (CT) bone marrow were analyzed by flow cytometry using lineage- and stage-specific antibodies. Donor cells were identified using antibodies to donor-specific alloantigen Ly-5.2 and subsequent population analyses were performed on an Ly-5.2–positive gate.
Data presented are the percentages of cells staining positive for specific surface antigens within the total Ly-5.2–positive population analyzed.
Population cell numbers (× 107) are shown in parentheses and bone marrow data are expressed on a per femur basis.
P < .005.
P < .05.